证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司投资者关系活动记录表 2023 年度业绩说明会 编号：2024-001 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他：线上交流活动 参与单位名称及 人员姓名 网上投资者 时间 2024 年 4 月 25 日 15:00-17:00 地点 全景网"投资者关系互动平台"（http://rs.p5w.net） 上市公司接待人 员姓名 董事长、总经理—林武辉 独立董事—王琳琳 财务负责人—倪海龙 董事会秘书—杨高锋 保荐代表人—姚奔 投资者关系活动 主要内容介绍 问：公司提议可转债下修价格，连续几次被投资者否定。已 经充分反映出投资者的意愿了。请问，接下来公司在 2 个月 内是否还将提议下修呢？ 答：尊敬的投资者，您好，董事会提议下修可转债的初衷是 兼顾股票投资者和债券投资者的利益，公司尊重所有投资者 的选择，后续可转债相关信息以公告为准，感谢您的关注。 问：尊敬的领导，作为中小投资者，有以下问题：1、公司今 年两次提议下修，均已失败告终。这在可转债市场实属罕见 ...

Financial Performance - The company's revenue for Q1 2024 was ¥258,678,766.77, a decrease of 0.56% compared to ¥260,137,982.34 in the same period last year[6] - Net profit attributable to shareholders was ¥23,018,894.92, down 13.74% from ¥26,685,502.18 year-on-year[6] - Basic and diluted earnings per share decreased by 14.29% to ¥0.12 from ¥0.14 in the same period last year[6] - The net profit for Q1 2024 was CNY 25,038,557.69, a decrease of 16.3% compared to CNY 30,005,182.04 in Q1 2023[21] - The total comprehensive income for Q1 2024 was CNY 25,038,557.69, down from CNY 30,005,182.04 in the previous year[21] - The operating profit for the quarter was CNY 31,240,274.07, a decline of 9.5% from CNY 34,329,789.87 in Q1 2023[22] Cash Flow - The net cash flow from operating activities was -¥27,125,489.87, a significant decline of 223.80% compared to ¥21,911,042.83 in the previous year[6] - Cash flow from operating activities showed a net outflow of CNY -27,125,489.87, contrasting with a net inflow of CNY 21,911,042.83 in Q1 2023[22] - The company reported a significant decrease in cash flow from financing activities, totaling CNY 40,257,263.16, down 94.13% from CNY 685,774,692.88 in the same period last year[11] - The cash flow from financing activities resulted in a net outflow of CNY -36,416,816.90, a significant decrease from a net inflow of CNY 655,238,382.54 in Q1 2023[23] - The company incurred a net cash outflow from investing activities of CNY -17,507,816.21, compared to CNY -99,766,297.98 in the same period last year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,948,889,759.38, down 1.26% from ¥2,986,593,236.85 at the end of the previous year[6] - Total liabilities decreased to CNY 1,007,431,613.75, down 5.29% from CNY 1,063,708,777.73[17] - Cash and cash equivalents decreased by CNY 80,858,585.96, a decline of 114.03% compared to an increase of CNY 576,438,107.42 in the previous year[11] - Cash and cash equivalents at the end of the period were CNY 624,411,515.57, down from CNY 878,534,040.79 at the end of Q1 2023[23] Expenses - Management expenses increased by 30.97% to ¥17,265,688.92, primarily due to higher employee costs[10] - Financial expenses surged by 166.33% to ¥7,835,489.35, mainly due to increased amortization costs related to convertible bonds[10] - The company’s income tax expense increased by 41.22% to CNY 6,210,598.89 from CNY 4,397,727.11 in the same period last year, primarily due to the timing of R&D expense deductions[11] Investment and R&D - The company continues to invest in R&D, with expenses amounting to CNY 8,326,725.04 for the quarter[18] - The company recovered investment cash of CNY 94,200,000.00, an increase of 93.81% from CNY 48,605,000.00 year-on-year[11] - Cash flow from investing activities totaled CNY 94,552,627.56, up 91.36% from CNY 49,411,747.31 in the previous year[11] Credit and Impairment - The company recorded a 312.93% increase in credit impairment losses, amounting to -¥1,158,505.63, attributed to higher provisions for bad debts[10] - The company reported a credit impairment loss of CNY -1,158,505.63, indicating a deterioration in asset quality compared to the previous year[22]

更多资料加入知识星球：水木调研纪要关注公众号：水木纪要 海顺新材 20240418_原文 2024年04月19日13:12 发言人 00:01 感谢大家参加本次会议，会议即将开始，请稍后一证券海顺新材 2023 年报业绩交流会，目前 则在会所正处于静音状态，下面开始播报声明，本次会议为中信证券白名单会议，仅限受邀客 户参会。未经中信证券和演讲嘉宾书面许可，任何机构和个人不得以任何形式将会议内容和相 关信息对外公布、转发、转载、传播、复制、编辑、修改等。如有上述违法行为，中信证券保 留追究相关方法律责任的权利。 发言人 00:38 好的，各位投资人，大家下午好，我是中信金融的分析师郭毅。今天我们也是非常荣幸的请到 了海顺新材的董轶杨总，来和我们一起进行业绩会后的这样一个交流。本次会议一起主持场电 话会议的还有中信信金的首席分析师李经理，李老师以及我的同事冯博佳。 发言人 00:55 较上年的同期增长 0.82%。 发言人 01:38 实，为了这两个，这就是钉钉和我们的科创的项目，我们储备了大量的一个人才。那这一块的 更多一手调研纪要和研报数据加V：shuinu9870 更多资料加入知识星球：水木调研纪要关注公众 ...

| 证券代码：300501 | 证券简称：海顺新材 | 公告编号：2024-051 | | --- | --- | --- | | 债券代码：123183 | 债券简称：海顺转债 | | | | 是否为控 | 本次 | 占其 | 占公司 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东或 | 解除 | 所持 | 可转债 | 质押起 | 解除质 | | | 名称 | 第一大股 | 质押 | 可转 | 比例 | 始日 | 押日期 | 质权人 | | | 东及其一 | 数量 | 债比 | （%） | | | | | | 致行动人 | （张） | 例（%） | | | | | | | | | | | 2024 年 | 2024 年 | 云南国际 | | 林武辉 | 是 | 300,0 00 | 17.22 | 4.74 | 3 月 22 | 4 月 17 | 信托有限 | | | | | | | 日 | 日 | 公司 | | 合计 | - | 300,0 | 17.22 | 4.74 | - | - | - | | | | 00 ...

二、关于募集资金年度存放与使用情况的专项报告 ……………第 3—14 页 上海海顺新型药用包装材料股份有限公司 2023 年度募集资金年度存放与使用情况鉴证报 告 天健会计师事务 所 Pan-China Certified Public Accountants 目 录 一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 三、附件………………………………………………………… 第 15—18 页 (一) 本所营业执照复印件……………………………………… 第 15 页 (二) 本所执业证书复印件……………………………………… 第 16 页 (三) 本所签字注册会计师执业证书复印件……………… 第 17—18 页 募集资金年度存放与使用情况鉴证报告 天健审〔2024〕2-164 号 上海海顺新型药用包装材料股份有限公司全体股东： 我们鉴证了后附的上海海顺新型药用包装材料股份有限公司（以下简称海顺 新材公司）管理层编制的 2023 年度《关于募集资金年度存放与使用情况的专项 报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供海顺新材公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本 ...

目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 上海海顺新型药用包装材料股份有限公司 2023 年度非经营性资金占用及其他关联资金往 来情况的专项审计说明 天健会计师事务 所 Pan-China Certified Public Accountants 二、非经营性资金占用及其他关联资金往来情况汇总表…………… 第 3 页 三、附件………………………………………………………………第 4—7 页 (一) 本所营业执照复印件……………………………………… 第 4 页 (二) 本所执业证书复印件……………………………………… 第 5 页 (三) 本所签字注册会计师执业证书复印件…………………第 6—7 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2024〕2-165 号 上海海顺新型药用包装材料股份有限公司全体股东： 我们接受委托，审计了上海海顺新型药用包装材料股份有限公司（以下简称 海顺新材公司）2023 年度财务报表，包括 2023 年 12 月 31 日的合并及母公司资 产负债表，2023 年度的合并及母公司 ...

Financial Performance - The net profit attributable to shareholders increased by 16.47% to CNY 32,907,068.87 for the current period[10] - The total profit for the period was approximately ¥98 million, a slight decrease from ¥98 million in the previous period[37] - Net profit attributable to shareholders was approximately ¥75.83 million, down from ¥83.28 million year-over-year, representing a decrease of about 8.7%[37] - The total comprehensive income for the period was approximately ¥83.09 million, compared to ¥88.25 million in the previous period[37] - The company reported a tax expense of approximately ¥14.91 million, an increase from ¥9.96 million in the previous period[37] Assets and Equity - The company's total assets increased by 25.42% year-on-year, reaching CNY 2,891,422,096.04[10] - The company's equity attributable to shareholders increased by 14.08% to CNY 1,821,378,591.60[10] - The company's equity attributable to shareholders rose to ¥1,821,378,591.60 from ¥1,596,620,328.83, an increase of approximately 14.0%[35] Cash Flow - The operating cash flow net amount decreased by 92.88% to CNY 3,841,952.56 compared to the same period last year[10] - The company reported a net cash inflow from financing activities of approximately ¥588.14 million, compared to a net outflow of ¥82.21 million in the previous period[39] - Cash flow from operating activities was not detailed but is critical for assessing operational efficiency[39] - Operating cash inflow for the current period was $741,312,789.73, a decrease of 3.9% from $771,067,723.75 in the previous period[52] - Net cash flow from operating activities was $3,841,952.56, significantly down from $53,983,974.44 in the previous period[52] Investments and Financing - The company issued convertible bonds, resulting in a cash inflow from financing activities of CNY 750,016,076.36, a 595.45% increase[5] - The financial expenses increased by 197.33% to CNY 11,143,921.65, mainly due to the recognition of financing costs from the issuance of convertible bonds[5] - Cash inflow from investment activities totaled $70,232,116.84, down 68.5% from $223,437,374.11 in the previous period[52] - Cash paid for investments was $109,005,000.00, a decrease from $280,890,000.00 in the previous period[52] Revenue and Costs - Total operating revenue for the period reached ¥758,017,323.85, an increase from ¥713,996,348.75 in the previous period, representing a growth of approximately 6.1%[36] - Total operating costs amounted to ¥671,259,683.41, up from ¥621,293,298.22, indicating an increase of about 8.1%[36] - The net profit margin remained stable with operating profit at ¥98,261,941.35, slightly up from ¥98,236,546.57 in the previous period[36] Shareholder Information - The company had a total of 16,355 common shareholders at the end of the reporting period[29] - The largest shareholder, Lin Wuhui, holds 29.98% of the shares, amounting to 58,019,499 shares[29] Other Income and Expenses - Non-operating income from the disposal of non-current assets amounted to ¥36,791.07 for the current period, with a total of ¥31,618.24 from the beginning of the year to the end of the reporting period[11] - The company recognized government subsidies of ¥4,830,377.57 in the current period, totaling ¥9,467,389.23 from the beginning of the year to the end of the reporting period[11] - The fair value changes of trading financial assets and liabilities resulted in a gain of ¥152,543.60 for the current period, with a total of ¥415,755.48 year-to-date[11] - The company reported a loss of ¥110,242.51 from other operating income and expenses for the current period, with a total loss of ¥167,007.40 year-to-date[11] - The total amount of other non-recurring gains and losses was reported as ¥15,498,970.45 for the year-to-date period[14]

Financial Performance - The company's operating revenue for 2023 was CNY 1,020,872,006.74, representing a 0.82% increase compared to CNY 1,012,601,235.55 in 2022[21]. - Net profit attributable to shareholders decreased by 16.61% to CNY 85,441,741.28 in 2023 from CNY 102,461,491.00 in 2022[21]. - The net profit after deducting non-recurring gains and losses was CNY 68,444,591.61, down 26.91% from CNY 93,649,802.79 in the previous year[21]. - The net cash flow from operating activities was CNY 100,596,592.11, a decrease of 26.55% compared to CNY 136,957,656.04 in 2022[21]. - Total assets increased by 29.55% to CNY 2,986,593,236.85 at the end of 2023, up from CNY 2,305,352,111.13 at the end of 2022[21]. - The company's net assets attributable to shareholders rose by 14.68% to CNY 1,831,064,236.93 at the end of 2023, compared to CNY 1,596,620,328.83 at the end of 2022[21]. - The basic earnings per share decreased by 16.98% to CNY 0.44 in 2023 from CNY 0.53 in 2022[21]. - The company achieved a total revenue of ¥1,020,872,006.74 in 2023, representing a year-on-year growth of 0.82%[52]. - Net profit attributable to shareholders decreased by 16.61% to ¥85,441,741.28, primarily due to increased financing costs and expanded production capacity[52]. - Revenue from new pharmaceutical packaging materials accounted for 91.79% of total revenue, with a year-on-year increase of 2.75%[57]. - Domestic sales contributed 89.06% of total revenue, with a slight increase of 0.09% compared to the previous year[57]. - The company reported a total sales volume of 33,408,530.94 kg, which is a 0.86% increase from the previous year[59]. - The company reported a total revenue of 1,007 million in the latest financial year[138]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a year-over-year growth of 20%[196]. Market and Industry Trends - The pharmaceutical packaging materials industry in China has surpassed a market size of 100 billion yuan, reflecting stable growth in market demand[32]. - The company focuses on high-barrier, low-adsorption, and anti-corrosion packaging materials, aiming to provide professional and precise packaging solutions for clients[36]. - The government has introduced a series of regulations to enhance the quality control standards for pharmaceutical packaging materials, requiring companies to meet higher quality thresholds[34]. - The introduction of smart packaging and anti-counterfeiting technologies is encouraged to promote industry innovation and upgrade[35]. - The government is guiding the pharmaceutical packaging industry towards consolidation and cluster development to increase industry concentration[35]. - The company is actively exploring packaging solutions in new consumption and new energy sectors, developing a series of innovative packaging materials[42]. - The company aims to enhance its export business, with a target of increasing export sales by 99.48% in the next fiscal year[107]. - The company plans to expand its market presence by launching new products, including advanced PVC and PVDC composite materials, targeting a 30% increase in production capacity by 2024[108]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[196]. Research and Development - The company has successfully applied for and obtained 152 patents, including 21 invention patents and 126 utility model patents, covering key areas such as basic material research and production process improvements[48]. - Research and development expenses increased by 13.17% to ¥50,351,367.93, indicating a focus on innovation and product development[66]. - The company is developing a new type of high-temperature sterilization liquid packaging composite film, which has completed preliminary feasibility studies and is currently in the small batch trial production stage[67]. - The company is also working on a new anti-counterfeiting PTP aluminum foil, which has completed feasibility studies and is in the customer feedback stage for small batch production[68]. - The company is committed to independent research and development, ensuring that new products meet stringent industry standards[69]. - The company is focusing on enhancing the performance of its packaging materials to ensure they meet various application environments[69]. - The company is committed to advancing its R&D efforts to align with international sustainability initiatives and market trends[70]. - The company plans to invest 100 million yuan in R&D for new technologies aimed at enhancing product efficiency[148]. Corporate Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operation from its controlling shareholders[131]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with governance standards[131]. - The company emphasizes transparency in information disclosure, utilizing multiple platforms to ensure equal access for all shareholders[133]. - The company has conducted online investor communication sessions on April 7, 2023, and August 29, 2023, discussing business development and strategic direction[133]. - The company has established specialized committees within the board to provide scientific and professional advice for decision-making[132]. - The company has implemented a "Quality Return Dual Improvement" action plan, although details on its execution were not disclosed[129]. - The management team includes experienced professionals with backgrounds in finance and materials, such as Lin Wuhui, who is the chairman and general manager[139]. - The management emphasized the importance of sustainability in new strategies, aiming for a 30% reduction in carbon footprint by 2025[148]. Environmental Responsibility - The company adheres to multiple environmental protection laws, including the Air Pollution Prevention Law and the Water Pollution Prevention Law, ensuring compliance in its operations[182]. - The company has implemented effective measures to prevent and control environmental risks in accordance with relevant laws and regulations[188]. - The company has invested in waste gas treatment equipment and continuous monitoring systems to ensure compliance with environmental laws[188]. - The company is committed to environmental responsibility, following strict regulations and maintaining a high standard of operational compliance[182]. - The company focuses on producing high-performance, low-carbon, and environmentally friendly packaging materials, such as recyclable composite materials[190]. - The company has committed to reducing carbon emissions by 25% by 2025 as part of its sustainability strategy[196]. Employee and Talent Management - The company has established a performance-based salary system, adjusting employee compensation annually based on company performance and individual contributions[166]. - The company has implemented a comprehensive welfare system, including social insurance and various employee benefits, to retain talent[166]. - The company emphasizes training programs for new employees and marketing personnel to enhance skills and knowledge[167]. - The total number of employees at the end of the reporting period is 896, with 24 in the parent company and 343 in major subsidiaries[164]. - The professional composition includes 555 production personnel, 98 sales personnel, 125 technical personnel, 29 financial personnel, and 89 administrative personnel[165]. - The educational background of employees shows 19 with master's degrees or above, 152 with bachelor's degrees, 186 with associate degrees, and 539 with high school or lower education[165]. Strategic Initiatives - The company plans to continue expanding its market presence and developing new products, although specific details on future strategies were not disclosed in the report[31]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million yuan allocated for potential deals[148]. - The company aims to enhance its R&D efforts in high-barrier packaging materials, focusing on pharmaceutical, medical, new consumption, and new energy sectors, with a commitment to developing recyclable composite materials and functional polyolefin film materials[119]. - The company will deepen cooperation with upstream and downstream enterprises in the industry chain to optimize supply chain management, improve raw material supply stability, and reduce production costs[116].

上海海顺新型药用包装材料股份有限公司 2023年度监事会工作报告 2023 年度，上海海顺新型药用包装材料股份有限公司（以下简 称"公司"）第五届监事会严格按照《公司法》《证券法》《公司章 程》《监事会议事规则》及有关法律、法规规定，认真履行监督职责， 监事会成员列席了公司董事会和股东大会，对公司依法运作情况和公 司董事、高级管理人员履行职责情况进行监督，有效发挥了监事会职 能，维护了公司及股东的合法权益。现将公司 2023 年监事会工作情 况报告如下： 一、监事会工作情况 1、列席董事会会议及出席股东大会情况 报告期内，全体监事列席了公司召开的13次董事会会议，出席了 召开的1次股东大会，并对股东大会召开程序以及所作决议进行了监 督。 | 序 号 | 会议名称 | 召开时间 | 审议议案 | | --- | --- | --- | --- | | 1 | 第五届监事会 | 2023年1月9日 | 《关于延期归还闲置募集资金并继续 | | | 第二次会议 | | 用于暂时补充流动资金的议案》 | | 2 | 第五届监事会 | 2023年3月20日 | 《关于进一步明确公司向不特定对象 | | | 第三次会议 ...

上海海顺新型药用包装材料股份有限公司 2023 年度内部控制自我评价报告 上海海顺新型药用包装材料股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部 控制监管要求（以下简称"企业内部控制规范体系"），结合本公司 （以下简称"公司"）内部控制制度和评价办法，在内部控制日常监 督和专项监督的基础上，我们对公司截止 2023 年 12 月 31 日（内部 控制评价报告基准日）内部控制有效性进行了评价。 一、重要声明： 按照企业内部控制规范体系的规定，建立健全和有效实施内部控 制、评价其有效性、并如实披露内部控制自我评价报告是公司董事会 的责任。监事会对董事会建立和实施内部控制进行监督。各管理层负 责组织领导企业内部控制的日常运行。公司董事会、监事会及董事、 监事、高级管理人员保证本报告内容不存在任何虚假记载、误导性陈 述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及 连带法律责任。 公司内部控制的目标是合理保证经营合法合规、资产安全、财务 报告及相关信息真实完整，提高经营效率和效果，促进实现发展战略。 由于内部控制存在固有局限性，故仅能对实现上述目标提供合理保证。 由于市场 ...